Google Analytics counts our visits, with cookies. No thanks turns it off and removes its cookies; in Europe, the UK, Switzerland and India, or wherever we cannot tell where you are, it stays off unless you accept. Cookie Notice

Advertise
PRICES

← Back to NewsDesk

AI summary of a third-party reportBullishNewsDesk

Isomorphic Labs raises $5bn Series C to push AI-designed drugs into trials

The DeepMind spin-out has raised $5bn in a round co-led by Greenoaks and Sequoia Capital, as it seeks to move its AI-designed drug candidates into clinical trials.

InvestIn.News NewsDesk · 1 min read
Share
Picture from Techcrunch for: Isomorphic Labs raises $5bn Series C to push AI-designed drugs into trials
Image: Techcrunch
Original reporting: Ram Iyer, Techcrunch

Key points

  • The Series C was co-led by Greenoaks and Sequoia Capital, with Andreessen Horowitz joining as a new investor.
  • Isomorphic reported positive preclinical results in oncology and immunology from its AI drug-design engine.
  • The raise follows a $2.1bn Series B in May; the company did not disclose its new valuation.

Isomorphic says its programme has produced positive preclinical results in oncology and immunology, and it has struck deals with Eli Lilly, Novartis and Johnson & Johnson.

The new money follows a $2.1bn Series B in May and will fund further development of the drug-design engine and a push into more types of medicine. It is the first raise since founder and chief executive Demis Hassabis stepped back from running DeepMind to concentrate on drug discovery, taking a chairman role there. Hassabis and John Jumper, then a DeepMind director, shared the Nobel Prize in chemistry for the AlphaFold work.

Read the full story on Techcrunch

Live updates on NewsFeeds:AIFrom our AI Hub: Is ChatGPT, Claude or Gemini down?, AI API prices, new AI modelsDesk editor: Keshav Aggarwal (accountable for this page; this summary was not edited by hand)

How this was produced: an AI model wrote this summary of Techcrunch’s report, which we credit and link above. Read our Editorial and AI policy. Spotted a mistake? See Corrections.

Not investment advice. Read the risk disclaimer.

← Back to NewsDesk